Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

OncoGenex/Teva Alter Late-Stage Custirsen Program

Mar 01 2012

• By Lisa LaMotta

Related Content

Zytiga Study Supports Expansion To Early Patient Population

Mar 08 2012

Prostate Cancer Market Snapshot: More Than Provenge

Nov 22 2010

OncoGenex Aims To Move OGX-011 Into Phase III For Hormone Refractory Prostate Cancer In Early 2009

Dec 03 2008

Related Companies

Teva Pharmaceutical Industries Ltd.

Achieve Life Sciences, Inc.

Johnson & Johnson

Sanofi

Ionis Pharmaceuticals, Inc.

Additional Topics

Clinical Trials BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window